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Abstract
Background: Patients with intravascular lymphoma (IVL) frequently have neurological signs and symptoms. Prompt
diagnosis and treatment is therefore crucial for their survival. However, the spectrum of neurological presentations
and their respective frequencies have not been adequately characterized. Our aim is to document the spectrum of
clinical symptoms and their respective frequencies and to create a clinical framework for the prompt diagnosis of IVL.
Methods: A comprehensive meta-analysis of 654 cases of IVL published between 1957 and 2012 was performed to
provide better insight into the neurological presentations of this disease. Neurologic complications were mainly
divided into central nervous system (CNS) and peripheral nervous system (PNS) presentations.
Results: There were no differences in occurrences of CNS IVL based on gender or geographic locations (Asian
Vs non-Asian). However, most patients with CNS IVL were younger than 70 years of age (p < 0.05). Our limited
data do not support the treatment efficacy of methotrexate.
CNS symptoms were seen in 42 % of all cases. The most common CNS complications identified were cognitive
impairment/dementia (60.9 %), paralysis (22.2 %), and seizures (13.4 %). PNS complications were seen in 9.5 % of cases.
Out of these, muscle weakness (59.7 %), neurogenic bladder (37.1 %), and paresthesia (16.1 %) were the most
common presentations.
Conclusions: CNS complications are more common among IVL patients. Out of these, dementia and seizures
outnumber stroke-like presentations.
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Background
Intravascular lymphoma (IVL) is a rare, aggressive sys-
temic B-cell lymphoma first described by Pfleger and
Tappeiner in 1959 [1]. IVL has an estimated annual inci-
dence of 0.5 cases per 1,000,000 population [2]. The
disease is characterized by selective growth of lymphoma
cells within the lumina of vessels, particularly small- and
medium-sized blood vessels [3]. The unique tropism of
these cells to those sites is due to the absence of CD29
and CD54 surface ligands, which may possibly limit the
ability to cross the endothelium. Proliferations of
large lymphoma cells within the lumen of small- to
medium-sized vessels are usually observed [3]. Over
time, these tumor foci may obstruct the arterial blood
supply to the distal locations causing ischemia in
various organs, resulting in systemic symptoms, neuro-
logical deficits, or both.
Depending on the target organ, the clinical signs and
symptoms can vary. The tumor also has the ability to
affect multiple organs and spread rapidly. Therefore, the
clinical presentation of patients with IVL can be highly
variable and unpredictable [4, 5]. Due to the rarity of
this tumor and lack of sensitive diagnostic methods, it is
difficult to diagnose in a timely fashion, sometimes
leading to its spread.
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If not diagnosed and treated early, patients with IVL
survive less than a year. In more than 50 % of the cases,
the diagnosis is made incidentally during autopsy [6].
However, in some cases where early diagnosis is made,
remission is a possibility with the timely administration
of systemic chemotherapy [6]. Therefore, proper under-
standing of the disease presentation will allow early diag-
nosis and prompt intervention. The rapid lethality of the
disease in the majority of patients precludes the possibility
of prospective studies. Published literature consists solely of
case reports and retrospective case series. As a result, we
performed a meta-analysis of the existing literature to com-
pile and analyze the pattern of clinical presentations of IVL.
Methods
A comprehensive literature search of intravascular lymph-
oma, angioendotheliomatosis, and intravascular lympho-
matosis was conducted in English language electronic and
print journals using PubMed, Medline, Paperchase, and
Web of Science from the year 1957 to 2012. It is worth
noting that in 1986 the nomenclature changed from “ma-
lignant angioendotheliomatosis” to “intravascular lympho-
matosis.” Cases were not included if they were not in
English or were not human studies. Also, cases were not
utilized if they did not list the symptoms demonstrated by
the patient upon presentation. For each case, the presenta-
tions were recorded and further classified as central ner-
vous system (CNS), peripheral nervous system (PNS), or
non-neurologic. The list of cases we utilized is attached as
a supplementary file.
Source data
Source data of this publication are presented in Add-
itional file 1: Table S1.
Statistics
Two-tailed Wilcoxon rank sum test was used to compare
CNS, PNS, and other cases of Asian, non-Asian patients
and treatment efficacy of methotrexate use.
Results
Patient characteristics
A total of 654 patients were included in this study (Add-
itional file 1: Table S1). While 316 (48 %) patients pre-
sented with various non-neurologic symptoms, neurologic
complications were observed in more than half of the
population or 338 patients (52 %). Of those, 276 (82 %) pa-
tients presented with CNS symptoms, 62 (19 %) patients
presented with PNS symptoms, and 316 (48 %) patients
presented with various non-neurologic symptoms. Relative
to the number of CNS patients were PNS only patient
number was lesser. Due to the small population size of the
PNS group and its similarity to the CNS than with other
sites, these patients were combined with the CNS cohort.
The study group consisted of 137 women and 133 men
(p = 0.43). The median age for men was 63 years (range =
17 – 86), and for women, 62 years (range = 23 – 88).
The time from symptom to death between IVL patients
with age less than 70 years (n = 193) was 15 months (range
1 – 110) while IVL patients with age greater than or
equal to 70 years (n = 77) was 14 months (range 0 – 63)
(P = 0.0911). The overall survival between IVL patients
with age less than 70 years was 12 months (range 0 – 96)
versus IVL patients with age greater than or equal to
70 years was 10 months (range 0 – 63) (P = 0.1102). The
time from treatment to death for IVL patients with age
less than 70 years was 11 months (range 0 – 96) versus
patients with age greater than or equal to 70 years was
10 months (range 0 – 63) (P = 0.2068). By using an un-
supervised modified binary partitioning algorithm [7, 8],
the age cutoff yielding the greatest time from symptom to
death was age 46 years (P = 0.0284). The median time
from symptom to death with age less than or equal
to 46 was 13 months (range 3 – 54) versus 16 months
(range 0 – 110). By using the same partitioning algorithm,
the age cutoff yielding the greatest separation of overall
survival, though it did not reach statistical significance
was also 46 (P = 0.0786). The median overall survival with
age less than or equal to 46 was 9 months (range 1 – 52)
for patients with age less than or equal to 46, and
12 months (range 0 – 96) for patients with age greater
than 46. Finally, the optimal age cutoff that yields the
greatest separation for time from treatment to death was
also 46 (P = 0.0583) with median time from treatment
to death for patients with age less than or equal to
46 versus patients with age greater than 46 was 8 months
(range 1 – 52) and 11 months (range 0 – 96), respectively.
Methotrexate use
Median time from symptom to death for CNS metho-
trexate users (n = 6) was 15 months (range 9 – 28) ver-
sus 18 months (range 9 – 55) for other methotrexate
users (n = 6) (P = 0.9357). The median overall survival for
CNS methotrexate users was 14 months (range 1 – 28)
versus 16 months (range 8 – 24) for other methotrexate
users (P = 0.5204). The median time from treatment to
death for CNS methotrexate users was 11 months (range
1 – 28) compared with 9 months (range 1 – 24) for other
methotrexate users (P = 0.9358). CNS IVL patients who
used methotrexate (n = 6) had a median time from symp-
tom to death of 15 months (range 9–28) versus 16 months
(range 1–58) for CNS IVL patients who did not use
methotrexate (P = 0.9469). Likewise, the median overall
survival for CNS IVL patients on methotrexate was
14 months (range 1–28) versus 12 months (range 0–58)
for CNS IVL patients not on methotrexate (P = 0.9246).
Finally, the median time from treatment to death for CNS
IVL patients who used methotrexate was 11 months
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(range 1–28) versus 10 months (range 0–58) for CNS IVL
patients who did not use methotrexate (P = 0.9167).
Geographical Outcomes of IVL
Central nervous system, PNS and other manifestations
of ethnically Asian patients were 29.% and 71.% respect-
ively. CNS, PNS and other manifestations of ethnically
Non-Asian patients were 47 %, 2 %, and 51 % respect-
ively. PNS cases were eliminated from comparison due
to small sample size.
Asian (n = 34) and non-Asian (n = 43) CNS patients
were compared. The geographic differences failed to
become statistically significant (p > 0.05). IVL of other
locations among Asian and Non- Asian patients were
compared and determined statistically insignificant as
well (p > 0.05).
CNS complications
Cognitive impairment (including dementia and enceph-
alopathy) was the most common presenting symptom
and was reported in 168 (60.9 %) cases. Extremity par-
alysis (upper motor neuron) was seen in 61 (22.1 %) pa-
tients. Paralysis (upper motor neuron) included cases of
single extremity paralysis, hemiplegia, and quadriplegia.
Thirty-seven (13.4 %) patients presented with seizures
including myoclonic jerks and status epilepticus. CNS
complications are summarized in Table 1.
PNS complications
The most common symptoms involving the PNS were
those of muscle weakness 37 (59.7 %), neurogenic blad-
der 23 (37.1 %), and neuropathies 17 (27.5 %). Cauda
equina syndrome and conus medullaris syndrome were
seen in 9 (14.5 %) patients. Saddle anesthesia commonly
accompanying neurogenic bladder was seen in 6 (9.7 %)
cases. Table 2 summarizes some of the PNS symptoms
that IVL can mimic.
Immunological assessment differences
It has been shown that tumors such as nasopharyngeal
carcinomas are more commonly associated with Epstein-
Barr virus (EBV) infections in Asian patients [9]. Out of
84 Asian patients with CNS manifestations, 28 patients
did not know their EBV status. Twenty patients did not
have either EBV1 or 2. Eight patients (14 %) were positive
for EBV1, and 28 (50 %) were positive for EBV 2. Out of
the 203 non-Asian CNS patients, 55 did not have their
EBV status checked. Sixty three or 43 % of patients did
not have EBV 1 or 2. Only 2 patients or 0.01 % were posi-
tive for EBV1 and 83 or 56 % were positive for EBV2. The
results regarding EBV testing are summarized in Table 3.
These findings might indicate an association between
EBV2 and CNS IVL.
Discussion
Our study population, spanning five decades, consisted
of 654 patients. The majority of them (338 or 52 %) were
Table 2 Peripheral nervous system (PNS) clinical presentations
of intravascular lymphoma
PNS Symptoms Number Percent
Muscle Weakness/Numbness 37 59.70 %
Neurogenic Bladder/Incontinence 23 37.10 %




Saddle Anesthesia 6 9.68 %
Neuropathies 5 8.10 %
Horner’s Syndrome 4 6.45 %
Polyradiculopathy/Radiculopathy 4 6.45 %
Guillen Barre 2 3.22 %
Myopathies 1 1.63 %
Table 1 Central nervous system (CNS) clinical presentations of
intravascular lymphoma
CNS Symptoms Number Percent
Cognitive impairment/Dementia 168 60.90 %
Paralysis/paraplegia 61 22.1
Seizures 37 13.41 %
Vision disturbances 24 8.69 %
Ataxia 21 7.61 %
Stroke like symptoms 21 7.61 %
Headache 19 6.88 %
Myelopathy 16 5.78 %
Dysarthria 15 5.43 %
Sensory deficits 13 4.71 %
Hearing disturbances 12 4.35 %
Aphasia 11 3.99 %
Cranial Nerve Palsies 10 3.62 %
Dizziness/vertigo 8 2.99 %
Hyperreflexia 7 2.54 %
Motor deficits 5 1.81 %
Panhypopiutarism 5 1.81 %
Syncope 5 1.81 %
Psychosis 4 1.45 %
Antehypophyseal Failure 2 0.72 %
Positive Babinski 2 0.72 %
Dysphagia 2 0.72 %
Apraxia 2 0.72 %
Coma 1 0.36 %
Dystonia 1 0.36 %
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presenting with neurological symptoms; 276 patients
(42 %) presented with CNS symptoms and 62 (9.4 %)
presented with PNS symptoms. According to geographical
origin and variable clinical presentations, two main types
of IVLs are identified; they are the Asian and non-Asian
subtypes. As shown earlier, brain and skin were the most
common organs affected in both of them [10]. However,
occurrences of IVL between these two ethnicities failed to
show statistical significance during our earlier analysis [6].
In this report, we compared the site of first organ af-
fected between Asian and Non-Asian patients. During
that analysis, we compared CNS and other sites of Asian
and non-Asian patients. Time from initial symptoms to
death of Asian and non-Asian patients was the same
whether the initial presentation was at CNS or elsewhere
(p > 0.05, Table 4). Overall survival of Asian or non-Asian
patients was the same whether the initial presentation was
at CNS or elsewhere (p > 0.05, Table 5). Treatment did not
change their survival time (p > 0.05, Table 6). Murase and
Nakamura reported that cutaneous and CNS manifesta-
tions were common, but not extensively observed in Asian
IVL cases. They attributed their observation to the
minimal or lack of neurological findings in the clinical
presentation of these patients [11]. Our comparisons
did not support a difference between Asian versus
non-Asian patients.
The neurological symptoms varied according to the af-
fected brain area [12]. Most of the pathology seemed to
occur from ischemia due to vascular obstruction [13].
Among CNS symptoms of IVL, the most common pres-
entation was cognitive impairment/dementia, which was
seen in 60.9 % of patients. Stroke-like symptoms were
explained more elaborately in earlier publications [2, 5, 14].
However, our analysis indicated that stroke-like symptoms
were seen in only in 7.68 % or 21 patients. During most of
those encounters, these patients were suspected of having
strokes and valuable treatment time was lost. Presentations
of these patients were similar to a stroke but clinical pro-
gression was rapid which can also be explained by multiple
or multifocal strokes. Such a rapid presentation does not
usually leave room for clinical suspicion of IVL, therefore
diagnosis of CNS IVL can be missed.
Paralysis (22.1 %) and seizures (13.4 %), the second and
third most common presentations, respectively, were also
seen more frequently than stroke-like symptoms. Move-
ment disorders following IVL were rare (0.36 %).
Table 4 Comparison of asian and non-asian patients’ overall survival
Site Asian/Non-Asian Time from Symptom to Death (months) P-value
CNS Non-Asian 14 (1-54) n = 43 0.9305
Asian 18 (1-58) n = 34
Other Non-Asian 15 (0-87) n = 100 0.7208
Asian 14 (1-110) n = 93
Site Asian/Non-Asian Overall Survival (months) P-value
CNS Non-Asian 10 (0-52) n = 43 0.4146
Asian 15 (0-58) n = 34
Other Non-Asian 11 (0-84) n = 100 0.5446
Asian 11 (0-96) n = 93
Site Asian/Non-Asian Time from Treatment to Death (months) P-value
CNS Non-Asian 10 (0-52) n = 43 0.2858
Asian 15 (0-58) n = 34
Other Non-Asian 10 (0-84) n = 100 0.2597
Asian 11 (0-96) n = 93
Table 3 Epstein-Barr Virus (EBV) immunological results of intravascular lymphoma
Asian CNS Asian PNS Asian Other Non-Asian CNS Non-Asian PNS Non-Asian Other
Total Patients 84 1 216 203 9 219
EBV Unknown 28 0 52 55 6 48
EBV Absent 20 (35 %) 0 58 (35 %) 63 (43 %) 2 (66 %) 77 (45 %)
EBV 1 8 (14 %) 0 19 (12 %) 2 (0.01 %) 0 9 (0.05 %)
EBV 2 28 (50.0 %) 1 (100 %) 87 (53 %) 83 (56 %) 1 (34 %) 85 (50 %)
CNS central nervous system
PNS peripheral nervous system
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Although localized and less functionally limiting rela-
tive to a stroke, neurological manifestations such as apha-
sia, apraxia, paralysis and paraplegia can also be included
in the stroke category. Even after such amalgamation, the
total number of patients who presented in that broad cat-
egory was only 37 %, much lower than the patients who
presented with cognitive impairments. We admit that IVL
is rare; however, when a patient presents with rapidly pro-
gressive neurological manifestations or neurological mani-
festations that cannot be explained, IVL should be
suspected [15]. Findings from Glass et al also favored cere-
brovascular infarction (76 %) or stroke-like symptoms
more than sub-acute encephalopathy’s (27 %). Mental sta-
tus changes which can manifest with or without focal
signs were categorized under sub-acute encephalopathies
[15]. One reason for the difference in clinical manifesta-
tions was perhaps the smaller number of patients in the
study by Glass et al [15].
The most common PNS symptoms are muscle weak-
ness (59.7 %), neurogenic bladder (37.1 %), and neuropa-
thies (27.5 %), respectively. Although 62 patients (9.4 %)
had PNS symptoms, there were only 10 patients (0.01 %)
with IVL confined to PNS locations. The evolution of
neurological deficits is such that devastating CNS involve-
ment is usually followed by PNS involvement. Tumor pre-
dilection for CNS vasculature relative to PNS can be a
reason for this rapid migration. Seemingly, fewer patients
with PNS symptoms support this hypothesis. Most of the
PNS symptoms can be explained by CNS involvement
rather than primary PNS involvement per se. Direct or
indirect peripheral nerve involvement of IVL can mimic
many peripheral nerve system disease presentations and
therefore confuse clinicians (Table 3). The most frequent
peripheral nervous system manifestation was muscle
weakness. Tumor cell obstruction of moderate- to
small-sized peripheral vessels supplying large mixed
nerve roots can give rise to such a presentation. Simi-
lar IVL tumor cells were also identified at distal nerve
targets in between nerve roots and muscles. However,
the diagnosis of those was debated between IVL and
neurolymphomatosis (NL) although both disease entities
show a close relationship [16, 17]. Such observations war-
rant a more comprehensive study of IVL tumor cells at
the molecular level. A few patients, who were initially di-
agnosed when presenting with PNS symptoms and treated
in a timely fashion, survived before devastating CNS
symptoms emerged. Therefore, clinical suspicion of IVL
when patients present with PNS symptoms can potentially
halt the unrelenting neurologic deterioration in a clinically
meaningful way.
Earlier studies pointed out that various clinical presenta-
tions and lack of diagnostic algorithms are reasons why
more than 50 % of patients with IVL are diagnosed post-
mortem [18]. We attempted to draw a disease progression
pattern of nervous system IVL. We were unsuccessful due
to the rapid progression of the disease as well as under
reporting of the data. Therefore, until more elaborate clin-
ical diagnostic criteria are drawn, care givers and clinicians
should suspect IVL especially when patients show rapid
progression of CNS symptoms, or unexplained CNS,
PNS symptoms. More elaborate reporting of cases and
diagnostic tests will also aid in the prompt diagnosis and
treatment of this disease.
A study from Ferreri et al showed that patients with
IVL limited to the skin had better survival. They attrib-
uted the early diagnosis of the cutaneous variant to be
the main reason for this observation [10]. On the other
hand, 60 % of the CNS IVL diagnoses are made
Table 6 Comparisons of effect of Methotrexate use
Methotrexate Use Time from Symptom to Death (months) P-value
Yes 17.0 (2.4-55.0) n = 18 0.5154
No 14.0 (0.4-110.0) n = 249
Yes 17.0 (2.4-55.0) n = 18 0.4442
No + N/A 14.0 (0.4-110.0) n = 258
No 14.0 (0.4-110.0) n = 249 0.5887
Yes + N/A 16.0 (1.7-55.0) n = 27
Methotrexate Use Overall Survival (months) P-value
Yes 15.5 (1.0-44.0) n = 18 0.3677
No 11.0 (0.1-96.0) n = 249
Yes 15.5 (1.0-44.0) n = 18 0.3164
No + N/A 10.1 (0.1-96.0) n = 258
No 11.0 (0.1-96.0) n = 249 0.9292
Yes + N/A 10.0 (1.0-44.0) n = 27
Methotrexate Use Time from Treatment to Death (months) P-value
Yes 13.0 (1.0-44.0) n = 18 0.7858
No 10.1 (0.1-96.0) n = 249
Yes 13.0 (1.0-44.0) n = 18 0.7208
No + N/A 10.0 (0.1-96.0) n = 258
No 10.1 (0.1-96.0) n = 249 0.5852
Yes + N/A 9.0 (1.0-44.0) n = 27
Table 5 Comparisons of effect of methotrexate use
Methotrexate Use Time from Symptom to Death (months) P-value
Yes 15 (9 - 28) n = 6 0.9469
No + N/A 16 (1 - 58) n = 71
Methotrexate Use Overall Survival (months) P-value
Yes 14 (1 - 28) n = 6 0.9246
No + N/A 12 (0 - 58) n = 71
Methotrexate Use Time from Treatment to Death (months) P-value
Yes 11 (1 - 28) n = 6 0.9167
No + N/A 10 (0 - 58) n = 71
Fonkem et al. BMC Neurology  (2016) 16:9 Page 5 of 7
postmortem [6]. Therefore prompt diagnosis and treat-
ment is the key to turning the tables on CNS, PNS IVL.
Out of the patients who were diagnosed ante mortem,
69 % survived 8.7 + 1.4 months and 29 % were alive at
the time (range 5–48 months) their respective case re-
ports were written. These calculations favor better sur-
vival if prompt diagnosis of CNS IVL is made. Absence
of uniform radiological changes is a huge setback in
achieving the goal of rapid diagnosis. Although likely to
derive false negative results, MRI of the CNS should be
routinely performed on patients with a suspicion of IVL
to rule out more common types of neurologic diseases,
and to complete staging work up for later management
of the patient. Still, in the absence of neuro-radiological
findings, a high index of clinical suspicion and a timely
neurosurgical biopsy appear to be the common aspects
of achieving a diagnosis of IVL. Since biopsy is an inva-
sive test, it should be used sparingly.
We found no systematic studies confirming that CNS
IVL has a preference for frontal brain regions. However,
our observations show that the most frequent neurological
finding following IVL is cognitive impairment. Human
frontal and temporal lobes are relatively more responsible
for cognition than other parts of the brain. Based on that
observation, we hypothesize that CNS IVL might have a
preference to those areas. Same organ IVL recurrences
have been observed at a higher rate in CNS than in other
organs [6]. Such a pattern also supports the intrinsic bio-
logical differences between CNS IVL versus the other or-
gans. Few case reports exist of patients who have had ante
mortem brain biopsies. Some were done on the frontal,
cortical areas and they were positive for IVL [19]. Since
IVL cannot be diagnosed solely based on radiography
alone, identifying targets for biopsy will allow early
diagnosis and management. Finally, the World Health
Organization has classified this disorder as a sub-type of
large B-cell lymphoma [3]. However, T-cell variants are
rarely reported [20]. Most of the immunological markers
used were B-cell markers and the comparison derived no
new insights into the disease.
Fortunately, most of the cases of IVL that we reviewed
were sensitive to systemic chemotherapy. We have previ-
ously reported that the addition of rituximab has more
than doubled, and the combination of rituximab and
doxorubicin has tripled the median survival rates of the
same patient cohort [6]. It has also been shown that
methotrexate is the most effective drug against primary
central nervous system lymphomas [21, 22]. During our
comparisons, methotrexate treatment did not change
time from initial symptom to death, time from treatment
to death or overall survival time (p > 0.05, Table 6). How-
ever, other studies geared more to test treatment effect-
iveness than ours showed that, methotrexate produces a
response rate of 52–88 % as monotherapy and this
response rate increases drastically to 70–94 % when
combined with other medications [23–25]. High doses
of methotrexate combined with rituximab and doxorubi-
cin derive better results [6]. However, recent reports in-
dicate methotrexate-resistant strains are emerging [26].
This is concerning because of our limited understanding
of IVL. We should try to increase our knowledge base of
IVL before resistance becomes rampant.
Most of the neurologic presentations have only been
described in case studies. Meta-analysis of existing cases
and case series was the only way to fully characterize the
spectrum of neurologic presentations. Our study com-
prised of clinical and pathological descriptions of case
reports and case series. To our knowledge, this is the
largest study of the neurologic presentations of IVL.
However, this study has several limitations. Due to the
rarity of this disease, prospective analysis could not be
done and published cases did not have uniform reporting
criteria. There are also inherent biases in meta-analysis
studies and great precaution was taken in order to
eliminate any bias that could affect the results as explained
in the methods section. At a minimum, we hope that
our analysis will serve as a basis for future prospective
studies of CNS IVL.
Conclusion
IVL is a rare aggressive systemic B-cell lymphoma which
over time can obstruct arterial blood flow to distal loca-
tions causing ischemia in various organs and subsequently
systemic symptoms, neurological deficits or both. This
study population consisted of 654 patients with IVL
spanning over five decades. The aim of this study was
to document the spectrum of clinical symptoms and
their respective frequencies to help create a clinical
framework for the prompt diagnosis of IVL. The majority
of cases showed neurological symptoms (52 % of patients
in this study). Of the patients presenting with neurological
symptoms, the most common presentation was cognitive
impairment/dementia (60.9 %). Paralysis (22.1 %) and sei-
zures (13.4 %) were the second and third most common
neurological presentations which were seen more fre-
quently than stroke-like presentations (7.8 %). We did not
find significant differences between Asian and non-Asian
populations in regard to time from initial symptoms to
death, overall survival or type of treatment. Due to
the rarity of this tumor and lack of sensitive diagnos-
tic methods, it is difficult to diagnose IVL in a timely
fashion and therefore proper understanding of the
disease presentation will allow early diagnosis and prompt
intervention. Due to the findings in this study, we
conclude that when a patient presents with rapidly
progressive neurological manifestations or neurological
manifestations that cannot be explained, IVL should
be suspected. At a minimum, we hope that our
Fonkem et al. BMC Neurology  (2016) 16:9 Page 6 of 7
analysis will serve as a basis for future prospective
studies of CNS IVL.
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